GoldenGolden
Advanced Search
Galapagos NV

Galapagos NV

Galapagos NV is a clinical-stage biotech company located in Mechelen, Belgium founded in 1999 by Onno van de Stolpe, Dinko Valerio, Onno Stolpe and Rudi Pauwels.

Founded in 1999, Galapagos NV is a clinical-stage biotech firm that develops and commercializes small molecule medicines. Their pipeline consists of several studies, and preclinical programs in cystic fibrosis, osteoarthritis, inflammation, and other indications.

Timeline

July 2019
Galapagos NV raises a $5,100,000,000 venture round from Gilead Sciences.
July 2019
Galapagos NV raises a $5,100,000,000 venture round from Gilead Sciences.
September 2018
Galapagos NV raises a $300,000,000 venture round.
January 2015
Galapagos NV raises a $2,989,712 grant from University of Antwerp.
January 2014
Galapagos NV raises a $3,467,863 grant.
January 2013
Galapagos NV raises a $3,228,795 grant.
October 2010
Galapagos NV raises a $4,424,941 grant.
March 2009
Galapagos NV raises a $1,000,993 grant from The Institute for the Promotion of Innovation by Science and Technology in Flanders.
October 2007
Galapagos NV raises a $6,218,992 grant.
1999
Galapagos NV was founded by Dinko Valerio, Onno Stolpe, Onno van de Stolpe and Rudi Pauwels.

Funding rounds

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
July 1, 2021
BioSpace
AgomAb Therapeutics NV, a privately held Belgian biotherapeutics company developing agonistic antibodies for the regeneration of damaged tissue, announced the appointment of two new members to its senior team to further strengthen the company's clinical, legal and corporate development capabilities.
Alex Keown
May 7, 2021
BioSpace
Galapagos NV will refocus its clinical pipeline and make some cost adjustments to save the company €150 million after disappointing studies assessing therapies for rheumatoid arthritis and idiopathic pulmonary fibrosis.
DelveInsight Business Research, LLP
April 19, 2021
www.prnewswire.com:443
/PRNewswire/ -- DelveInsight's "Global Kinase Inhibitor in Autoimmune Diseases Market" report provides a thorough comprehension and the Global Kinase Inhibitor...
Pomerantz LLP
March 3, 2021
www.prnewswire.com:443
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Galapagos NV ("Galapagos" or the "Company") (NASDAQ: GLPG). Such investors are...
Pomerantz LLP
February 19, 2021
www.prnewswire.com:443
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Galapagos NV ("Galapagos" or the "Company") (NASDAQ: GLPG). Such investors are...
Pomerantz LLP
December 10, 2020
www.prnewswire.com:443
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Galapagos NV ("Galapagos" or the "Company") (NASDAQ: GLPG). Such investors are...
BioSpace
June 5, 2020
BioSpace
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced new analyses from two clinical trials evaluating filgotinib, an investigational, oral, selective JAK1 inhibitor, in adults with psoriatic arthritis (PsA). The data from the dou
Alex Keown
May 21, 2020
BioSpace
A high dose of filgotinib, the JAK1 inhibitor under long-term development by Gilead Sciences and Galapagos NV, proved effective in a Phase IIb/III study as a treatment for patients with moderately to severely active ulcerative colitis.
Reuters Editorial
July 14, 2019
U.S.
Gilead Sciences Inc will invest $5.1 billion to raise its stake in Galapagos NV and partner with the Belgian-Dutch biotech firm to develop and commercialize its treatments for a ten-year period, the companies said on Sunday.
Reuters Editorial
July 14, 2019
U.S.
Gilead Sciences Inc will invest $5.1 billion to increase its stake in Galapagos NV and partner with the Belgian-Dutch biotech firm to develop and commercialize its treatments for a ten-year period, the companies said on Sunday.
Research and Markets
Invalid Date
www.prnewswire.com:443
DUBLIN, Feb. 13, 2019 /PRNewswire/ -- The "Dermatology Drugs Market by Treatment, by Drug, by Therapy Area, by Prescription Mode, by Distribution Channel, by...

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.